Implementation of a validated peripheral neuropathy screening tool in patients receiving antiretroviral therapy in Mombasa, Kenya

American Journal of Tropical Medicine and Hygiene

Volumn 83, Issue 3, 2010, Pages 565-570

  Mehta, Sapna A ^a   Ahmed, Aabid ^b   Kariuki, Beatrice W ^b   Said, Swaleh ^b   Omasete, Fanuel ^b   Mendillo, Megan ^a   Laverty, Maura ^a   Holzman, Robert ^a   Valentine, Fred ^a   Sivapalasingam, Sumathi ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Bomu Medical Centre   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; STAVUDINE;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; BRIEF PERIPHERAL NEUROPATHY SCREEN; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PERIPHERAL NEUROPATHY; POPULATION RESEARCH; PREVALENCE; RISK FACTOR; SCREENING TEST; SURVIVAL RATE; TENDON REFLEX; VALIDATION PROCESS; VIBRATION SENSE; CD4 LYMPHOCYTE COUNT; CHEMICALLY INDUCED DISORDER; CROSS-SECTIONAL STUDY; MULTIVARIATE ANALYSIS; VALIDATION STUDY;

HUMAN IMMUNODEFICIENCY VIRUS;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; KENYA; MALE; MULTIVARIATE ANALYSIS; PERIPHERAL NERVOUS SYSTEM DISEASES; RISK FACTORS;

EID: 77957035940     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2010.09-0629     Document Type: Article

References (18)

1. Ferrari S, Vento S, Monaco S, Cavallaro T, Cainelli F, Rizzuto N, Temesgen Z, 2006. Human immunodeficiency virus-associated peripheral neuropathies. Mayo Clin Proc 81: 213-219. (Pubitemid 43205776)
2. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Available at: http://www.who.int/ hiv/pub/guidelines/artadultguidelines.pdf. Accessed June 2, 2010.
3. Boulle A, Orrel C, Kaplan R, Van Cutsem G, McNally M, Hilderbrand K, Myer L, Egger M, Coetzee D, Maartens G, Wood R, 2007. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 12: 753-760. (Pubitemid 47235489)
4. Forna F, Liechty CA, Solberg P, Asiimwe F, Were W, Mermin J, Behumbiize P, Tong T, Brooks JT, Weidle PJ, 2007. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 44: 456-462. (Pubitemid 46555382)
5. Hawkins C, Achenbach C, Fryda W, Ngare D, Murphy R, 2007. Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr 45: 304-310. (Pubitemid 47012377)
6. Hoffmann CJ, Fielding KL, Charalambous S, Sulkowski MS, Innes C, Thio CL, Chaisson RE, Churchyard GJ, Grant AD, 2008. Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. AIDS 22: 67-74. (Pubitemid 350294879)
7. Millogo A, Lankoande D, Yameogo I, Yameogo AA, Sawadogo AB, 2008. Polyneuropathies in patients treated with HAART in Bobo-Dioulasso hospital, Burkina Faso [in French]. Bull Soc Pathol Exot 101: 11-13.
8. van Oosterhout JJ, Bodasing N, Kumwenda JJ, Nyirenda C, Mallewa J, Cleary PR, de Baar MP, Schuurman R, Burger DM, Zijlstra EE, 2005. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health 10: 464-470. (Pubitemid 40712431)
9. Wester CW, Kim S, Bussmann H, Avalos A, Ndwapi N, Peter TF, Gaolathe T, Mujugira A, Busang L, Vanderwarker C, Cardiello P, Johnson O, Thior I, Mazonde P, Moffat H, Essex M, Marlink R, 2005. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 40: 336-343. (Pubitemid 41533075)
10. Cherry CL, Wesselingh SL, Lal L, McArthur JC, 2005. Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology 65: 1778-1781.
11. Simpson DM, Kitch D, Evans SR, McArthur JC, Asmuth DM, Cohen B, Goodkin K, Gerschenson M, So Y, Marra CM, Diaz-Arrastia R, Shriver S, Millar L, Clifford DB, 2006. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology 66: 1679-1687. (Pubitemid 43964622)
12. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Available at: http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf. Accessed June 2, 2010.
13. Maritz J, Benatar M, Dave JA, Harrison TB, Badri M, Levitt NS, Heckmann JM, 2010. HIV neuropathy in South Africans: frequency, characteristics, and risk factors. Muscle Nerve 41: 599-606.
14. Wadley A, Price P, George J, Affandi J, Smith K, Kamerman P, eds. 2009. HIV-Associated Sensory Neuropathy: A Comparison of Rates and Risk Factors in Australia and South Africa. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 19-22, 2009, Cape Town, South Africa.
15. Cherry CL, Affandi JS, Imran D, Yunihastuti E, Smyth K, Vanar S, Kamarulzaman A, Price P, 2009. Age and height predict neuropathy risk in patients with HIV prescribed stavudine. Neurology 73: 315-320.
16. Keiser O, Anastos K, Schechter M, Balestre E, Myer L, Boulle A, Bangsberg D, Toure H, Braitstein P, Sprinz E, Nash D, Hosseinipour M, Dabis F, May M, Brinkhof MW, Egger M, 2008. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 13: 870-879. (Pubitemid 351813514)
17. Arrighi HM, Hertz-Picciotto I, 1994. The evolving concept of the healthy worker survivor effect. Epidemiology 5: 189-196. (Pubitemid 24073393)
18. Gonzalez-Duarte A, Robinson-Papp J, Simpson DM, 2008. Diagnosis and management of HIV-associated neuropathy. Neurol Clin 26: 821-832. (Pubitemid 352020492)